Senior Editor Owen Stretton talks to Professor Shankar Shiva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.

Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.

Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide.

Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields.

Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.

Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative.

Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”.

Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".

Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.

Prof Valerie Speirs (University of Aberdeen, Aberdeen, Scotland) discusses her Systematic Review on genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers in male breast cancer.

Prof Sameer Bakhshi, (All India Institute of Medical Sciences, New Delhi, India) discusses his Article on sex disparities in childhood cancer in India.

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Mark Lawler (Queen’s University Belfast, Belfast, UK) and Richard Sullivan (Kings College London, London, UK) discuss the European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission.

Samar Alhomoud (King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia) discusses her review on progress and remaining challenges for cancer control in the Gulf Cooperation Council.

Inge Marie Svane (Copenhagen University Hospital, Copenhagen, Denmark) discusses her Review on clinical advances and ongoing trials on mRNA vaccines for cancer treatment.

Eline Giraud and Elise Smolders from the (Radboud University Medical Center, Nijmegen, Netherlands) discuss their Review on QT interval prolongation potential of anticancer and supportive drugs.

Ignace Vergote (Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium) and Maria Kyrgiou (Imperial College London, London, UK) discuss their Series papers on gynaecological cancers.

David J Pinato (Imperial College London, London, UK) discusses the OnCovid registry study on the outcomes of the SARS-CoV-2 omicron variant outbreak among patients with cancer in Europe.

Wilfred Ngwa (Harvard Medical School, Boston, MA, USA; Johns Hopkins University, Baltimore, MD, USA; ICT University, Yaounde, Cameroon), Beatrice Wiafe-Addai (Peace and Love Hospital, Kumasi, Ghana), and David Kerr (University of Oxford, Oxford, UK) discuss the Lancet Oncology Commission on cancer in sub-Saharan Africa.

Georgios Lyratzopoulos (Institute of Epidemiology & Health Care at University College London, London, UK) discusses his population-based study on risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission.

Lisa Iezzoni (Massachusetts General Hospital, Boston, MA, USA) discusses her Series paper on disabilities and cancer and Jordan Marchak (Children’s Healthcare of Atlanta, Atlanta, GA, USA) discusses her Review on surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors.

Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.

Prof Yi-Long Wu (Guangdong Lung Cancer Institute, Guangzhou, China) and Prof Caicun Zhou (Shanghai Pulmonary Hospital, Shanghai, China) discuss the GEMSTONE 301 and GEMSTONE 302 trials on sugemalimab versus placebo in non-small-cell lung cancer.

Rebecca Fitzgerald (University of Cambridge, Cambridge, UK) discusses her Article on the use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance.

Elysia Alvarez (UC Davis Comprehensive Cancer Center, Sacramento, USA) discusses her Article on the analysis of the global burden of adolescent and young adult cancer in 2019.

Aju Mathew (Malankara Orthodox Syrian Church Medical College and Hospital, Kerala, India) discusses his Review on financial toxicity in cancer care in India.

David Pinato (Imperial College London, Hammersmith Hospital, London, UK) discusses his Article on prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection.

James Glasbey (UK NIHR Global Health Research Unit on Global Surgery, University of Birmingham, Birmingham, UK) discusses his Article on the effect of COVID-19 pandemic lockdowns on planned cancer surgery.

Manju Sengar (Tata Memorial Centre, India) and Christopher Booth (Queen’s University Cancer Research Institute, Canada) discuss their Article on the comparison between cancer drugs deemed essential by oncologists and those included in the WHO Essential Medicines List.

Series authors discuss the Global Cancer Control Networks Series on how high-income countries, particularly the UK and Canada, can help with cancer control in low-income and middle-income countries.

Rafael Cardoso and Hermann Brenner (German Cancer Research Center, Heidelberg, Germany) discuss their recent paper on colorectal cancer incidence, mortality, and stage distribution in Europe.

Takayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.

Roberto Orecchia (European Institute of Oncology IRCCS) discusses the ELIOT trial on intraoperative irradiation for early breast cancer.

Hedvig Hricak (Memorial Sloan Kettering Cancer Center), Andrew Scott (Olivia Newton-John Cancer Research Institute), Rifat Atun (Harvard TH Chan School of Public Health), and May Abdel-Wahab (International Atomic Energy Agency) discuss The Lancet Oncology’s Commission on Medical Imaging and Nuclear Medicine.

Ariana Znaor, International Agency for Research on Cancer, discusses her Article on breast and cervical cancers stage distributions in ten newly independent states of the former Soviet Union.

Sathira Perera (University of New South Wales, Australia) discusses his (and colleagues) Articles on the global use of cancer surgery.

Geke Hospers (University Medical Center Groningen, The Netherlands) discusses the RAPIDO trial Article published in The Lancet Oncology.

Annie Young (University of Warwick, UK) and Julia Challinor (University of California San Francisco, USA) present their two-paper Series on Oncology Nursing.

Robert Hiatt (University of California San Francisco, USA) discusses his and Naomi Beyeler’s (same University) Review on climate change and cancer.

Paul Sargos (Institut Bergonié, France) discusses the GETUG-AFU 17 trial and Andrew Kneebone (Royal North Shore Hospital and University of Sidney, Australia) the RAVES trial.

Lisa Bodei (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses the Review in The Lancet Oncology on molecular profiling of neuroendocrine tumours to predict response to peptide receptor radionuclide therapy.

Alexander Drilon (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a pooled analysis in The Lancet Oncology on the role of larotrectinib in patients with TRK fusion-positive solid tumours.

Ken Herrman (University Hospital Essen, Essen, Germany) discusses a Review in The Lancet Oncology on the role of injectable radiopharmaceuticals with anti-tumour effects.

Corneel Coens and Madeline Pe discuss recommendations from the SISAQOL Consortium for the analysis of patient-reported outcomes, published in a Policy Review in The Lancet Oncology.

Monica Koo (University College London, London, UK) discusses an Article in The Lancet Oncology on presenting symptoms of cancer and stage at diagnosis in patients in England.

Rifat Atun (Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA) discusses a Review in The Lancet Oncology on global patterns in public and philanthropic funding for childhood cancer research with Senior Editor Márcia Costa.

Partha Basu (International Agency for Research on Cancer, Lyon, France) discusses a Policy Review in The Lancet Oncology on cervical cancer prevention efforts in India.

David Palma and Anthony Nichols discuss the findings from their ORATOR trial on radiotherapy or robotic surgery for oropharyngeal squamous cell carcinoma.

New Zealand’s new interim Cancer Control Agency director, Diana Sarfati, discusses a series of five papers exploring cancer control in small island nations.

Eric Deutsch (Gustave Roussy Comprehensive Cancer Center, Villejuif, France) presents The Lancet Oncology’s latest series on advances in radioimmunotherapy for cancer.

Georgina Long (The University of Sydney, Sydney, NSW, Australia) discusses three papers from The Lancet Oncology on neoadjuvant approaches for melanoma treatment.

Jens Hillengass discusses the new International Myeloma Working Group consensus guidelines on optimal use of imaging methods for monoclonal plasma cell disorders.

Kee Yuan Ngiam (National University Hospital Singapore, Singapore) discusses a duo of papers exploring big data and machine-learning algorithms for healthcare delivery and pathology in oncology.

CS Pramesh discusses ten low-value or harmful practises that should be avoided in cancer care in India.

Bianca Hoeben discusses the latest guidelines from the SIOPE radiotherapy working group on vertebral radiotherapy dose in paediatric patients.

Anna Bibby joins The Lancet Oncology to discuss recent developments in the treament of malignant plural mesothelioma.

Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Talía Malagón discusses her modelling study which assesses the age at which to stop cervical cancer screening in older women and the remaining lifetime risk of cervical cancer.

Stein Kaasa and Jon Loge discuss their new Commission on palliative care.

Andre Ilbawi talks about his global analysis of available national cancer control plans with The Lancet Oncology.

A review in The Lancet Oncology asks whether patient reported outcomes in RCTs are consistent across their analysis, reporting, and interpretation. Author Madeline Pe discusses the findings.

Eva Steliarova-Foucher joins The Lancet Oncology to discuss the Europe-wide Automated Childhood Cancer Information System, and the increase in cancer incidence rates among children and adolescents.

Mark Souweidane joins The Lancet Oncology to discuss his dose-escalation study, assessing a convection-enhanced delivery for diffuse intrinsic pontine glioma.

Bo Jan Noordman joins The Lancet Oncology to discuss the findings from his study of residual disease detection in oesophageal cancer.

Fabio Conforti talks to The Lancet Oncology about a meta-analysis showing that a patient's sex can affect the efficacy of cancer immunotherapy.

Paul Kluetz from the US FDA discusses the issues surrounding the use of patient-reported outcomes in regulatory decision making.

Michael Hoeckel joins The Lancet Oncology to discuss his latest trial on the surgical treatment of vulvar carcinoma based on the theory of ontogenetic cancer fields.

Håvard Emil Danielsen joins The Lancet Oncology to discuss his latest paper on machine learning algorithms to analyse chromatin organisation as a prognostic marker for cancer.

Ross Camidge discusses RANO's papers on clinical trial design for patients with brain metastases.

John Field discusses a European position statement on lung cancer screening using low-dose CT.

Commission co-chairs Chi Van Dang and Elizabeth M. Jaffee discuss a new Lancet Oncology Commission on cancer treatment and care in the USA.

Ben Anderson talks about cancer care and cancer trends in Peru.

Ricky Sharma discusses results from three prospective trials on the use of selective internal radiotherapy for liver metastases from colorectal cancer.

Samra Turajlic discusses the contribution of small insertions and deletions to tumour-specific antigen analyses.

Percy Lee discusses the impact of prior radiotherapy on the efficacy of pembrolizumab when used to treat non-small cell lung cancer.

Martin Taphoorn outlines the importance of palliative care for patients with gliomas.

Sandro Porceddu discusses the new Lancet Oncology Series on head and neck cancer.  

Michele Cavo discusses the International Myeloma Working Group’s recommendations on the use of 18F-FDG PET/CT for patients with multiple myeloma and other plasma cell dyscrasias.

Lesley Seymour discusses the iRECIST guidelines for assessing tumour responses in immunotherapy trials.

Javier Torres-Roca and Louis Harrison join us to discuss their work on genome modelling and its uses in calculating the appropriate radiation dosage.

Ann Partridge talks about cancer survival in the USA.

Rafael Rossell discusses RET inhibitors and non-small cell lung cancer.

Brigitta Baumert discusses her article on quality of life in patients with high-risk, low-grade glioma.

Brian Rini discusses active surveillance for patients with metastatic renal cell carcinoma.

Shaji Kumar discusses updated consensus criteria from the International Myeloma Working Group for response and minimal residual disease assessment in multiple myeloma.

Catherine Sauvaget and Ryo Konno discuss Japan’s low uptake of screening programmes for breast and cervical cancer.

Anish Thomas discusses use of antibody-drug conjugates for cancer therapy.

Jean-Claude Dupont and François Doz discuss ethical issues in paediatric oncology clinical trials.

Michael Taylor discusses treatment approaches to the rare brain tumour that generally affects children, medulloblastoma.

Sibylle Loibl discusses the findings and clinical implications of the GeparSepto trial.

Dr. Richard Carvajal discusses aspects of treatment and research for rare cancers.

Discussion of two new treatment approaches to indolent lymphoma and mantle-cell lymphoma, haematological diseases with generally poor response to chemotherapy.

Hideho Okada discusses immunotherapy response assessment criteria in neuro-oncology. 

Rajendra Badwe discusses treatment options for metastatic breast cancer.

Harry Bear discusses the use of adjuvant and neoadjuvant bevacizumab in the treatment of early breast cancer.

Ane Appelt discusses adopting a watchful waiting approach for patients with rectal cancer who achieved a clinical complete response after chemoradiotherapy.

Amy Kreimer discusses HPV vaccine dosing schedules and cervical cancer prevention.

Nancy Lin discusses RANO Group’s new response assessment criteria checklist.

Rolando Herrero summarises three papers that constitute the HPV and cancer Series.

Jeffery Weber discuses advances in cancer drug development.

Dr Saro Armenian discusses long term health concerns for survivors of childhood cancers.

Jeff Bradley discusses standard verses high-dose radiation in conjunction with chemotherapy for patients with phase III non-small-cell lung cancer.

Dennis Slamon discusses advances in breast cancer treatment based on data from the PALOMA trial.

Charles Bennett discusses the development and regulatory landscape of biosimilar oncology drugs.

S Vincent Rajkumar of the Mayo Clinic discusses the updated disease definition of multiple myeloma.

Daniel M Green discusses the effect of treatment for childhood cancers on male fertility.

Naomi Lee discusses new research about depression and cancer with Michael Sharpe and Jane Walker.

Robert Hills discusses a meta-analysis of gemtuzumab ozogamicin for the treatment of adult myeloid leukaemia.

Jeremy Whelan from the National Cancer Research Institute discusses the underrepresentation of teenagers and young adults in clinical cancer trials.

Paul Spiegel discusses cancer in refugees in Jordan and Syria and how the UNHCR have addressed the provision of expensive cancer treatment.

Laura Essermann discusses cancer over-diagnosis and over-treatment.

Ian Krop discusses a phase III trial to assess efficacy of trastuzumab emtansine for women with recurrent HER2-positive breast cancer.

Michael Höckel joins Natalie Harrison to discuss how surgery based on ontogenetic staging is sufficient to control cervical cancer without additional radiotherapy.

Christopher Klenk and Heike E Daldrup-Link join Natalie Harrison to discuss ionising radiation-free techniques in cancer detection.

Jonathan Banks discusses the aims and implications of a study into public preferences for cancer testing.

Roberta de Angelis discusses the results and implications of the EUROCARE 5 study

Jayant Vaidya and Umberto Veronesi discuss the TARGIT and ELIOT trials of intraoperative radiotherapy for early breast cancer

Ramon Luengo-Fernandez discusses the cost of cancer care in the European Union.

Jesus San Miguel discusses a phase 3 trial comparing pomalidomide plus low-dose dexamethasone with high-dose dexamethasone in patients with multiple myeloma.

Ole Raaschou-Nielsen discusses the association between long-term exposure to ambient air pollution and lung cancer risk.

Perry Pickhardt discusses the value of CT colonography to determine whether small colorectal polyps will progress or not.

Thorsten Kuehn discusses the SENTINA study, concerning centinel lymph node biopsy before and after neoadjuvant chemotherapy in breast cancer.

Paul Goss presents an overview of The Lancet Oncology Commission on cancer prevention in Latin America.

Yael Mosse discusses a phase I study about the potential of targeted molecular therapy for childhood cancers.

Sulma Mohammed discusses a pilot study of breast cancer screening in rural Sudan.

Kathy Pritchard-Jones discusses a Series about paediatric oncology.

John Farley discusses a trial of the MEK inhibitor selumetinib for the treatement of low-grade serous carcinoma of the ovary and peritoneum.

Nicole Krekel discusses a trial which assesses ultrasound-guided breast conserving surgery in the management of breast cancer.

Anticancer drugs: doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours.

Asian Oncology Summit: Consensus guidelines on palliative care, kidney cancer, and colorectal cancer.

Discussion of a UK/French study into adult diabetes risk after radiation for childhood cancer.

Gustavo Ismael discusses subcutaneous versus intravenous administration of trastuzumab in patients with breast cancer.

Discussion of the oral MEK inhibitor trametinib in cancer treatment. .

Circulating tumour cells as a possible prognostic marker for non-metastatic breast cancer.

Matthias Kloor discusses the prevalence of mismatch repair-deficient crypt foci in Lynch syndrome.

Andrew Grulich discusses his paper looking at HPV infection and anal cancer.

The association between endometriosis and ovarian cancer.

The effect of chemotherapy in pregnancy on health outcomes in young children.

Discussion of updated guidelines for the appropriate use of opioids in the management of cancer pain.

HLA matching of transplanted umbilical-cord blood for treating leukaemia and myelodysplastic syndrome.

Comparison of CT colonography with conventional colonoscopy for colorectal cancer screening.

Discussion of a promising antiangiogenic approach for the treatment of ovarian cancer, and other highlights from the November issue.

October highlights, including discussion of the trial about the tyrosine kinase ALK and non-small-cell lung cancer.

David Collingridge launches The Lancet Oncology Commission on delivering affordable cancer care in high-income countries.

September issue highlights, including discussion of HPV testing and cytology.

The role of dignity therapy in end-of-life cancer care.

Emma Grainger with July highlights, and an interview about a trial assessing the value of zoledronic acid in the treatment of pre-menopausal early breast cancer.

June issue highlights, including faecal blood tests to assess future colorectal cancer risk, and of the 'dangerous liaison' between cancer and tuberculosis.

May highlights, including discussion of a phase II study about the treatment of B-cell lymphoma in very old patients.

April issue highlights, including the latest developments of the breast Health Global Initiative(BHGI), including an interview with BHGI Director Benjamin Anderson.

March issue highlights, including new data from the HERA trial about long-term efficacy of herceptin for early breast cancer.

Rob Brierley with February highlights, including the prevalence of depression among cancer patients.

January highlights, including automated verses manual cytology for detection of cervical cancers.

December issue highlights, including mammography screening for younger women with familial breast cancer.

November issue highlights, including an large-scale HPV genotype analysis with implications for cervical-cancer vaccine development, and the potential for discontinuation of imatinib treatment for people with chronic myeloid leukaemia.

Includes author interview about a trial comparing sentinal-lymph-node biopsy with axillary-lymph-node dissection in breast cancer treatment.

September issue highlights, including discussion of a possible association between hepatitis B infection and non-Hodgkin lymphoma in a Korean population.

August issue highlights, including bevacizumab for NSCLC, and cancer issues among people with mental illness.

Roy Herbst discusses the Zodiac trial, a phase 3 study assessing the efficacy of vandetanib for treating advanced non-small-cell lung cancer.

Emma Grainger discusses erlotinib as maintenance treatment for lung cancer, and IGF1 and risk of breast cancer.

The role of zoledronic acid with chemotherapy for early breast cancer and other issue highlights are discussed.

April issue highlights, including a genome-wide association study of lung cancer for never smokers.

March issue highlights, including hypofractionated radiotherapy for early breast cancer.

Discussion of phase I novel targeted therapy for sarcoma.

Emma Grainger with issue highlights and Kathy Albain discussing chemotherapy and tamoxifen for post-menopausal women with breast cancer.

Audrey Ceschia discusses issue highlights, including impact of HIV infection on cancer risk.

Discussion of new oncology management guidelines derived from didactic workshops at the Asia Oncology Summit 2009.

Rob Brierley discusses an antithrombolic agent for patients receiving chemotherapy for solid tumours.

Discussion of prostate cancer treatment, the PASSION-P trial, and a new Quackery column.

Rob Brierley discusses sunitinib for kidney cancer, and how bureaucracy is stifling UK clinical research.

Emma Grainger discusses bariatric surgery, weight loss, and cancer risk for obese people.

Audrey Ceschia discusses issue highlights, including treatment for nausea and vomiting from chemotherapy.

David Collingridge discusses research articles on prophylactic cranial irradiation for small-cell lung cancer, and the addition of temozolomide to radiotherapy for treating glioblastoma.

Rob Brierley discusses research articles on cancer survival in England, and the potential for ovarian cancer screening.

Emma Grainger discusses articles on myelodysplastic syndromes, circulating tumour cells and prostate cancer, and palliative stents for oesophageal cancer.

Rob Brierley discusses two research articles investigating genetic subtypes of childhood acute lymphoblastic leukaemia.

Emma Grainger discusses liver transplantation criteria, sorafenib for liver cancer in the Asia-Pacific, and NICE guidance on erlotinib for non-small-cell lung cancer.

David Collingridge discusses a research article comparing microsurgery with total excision for basal-cell carcinoma of the face, and other content highlights.

Rob Brierley introduces the latest issue, including research articles about prostate cancer and a review highlighting the importance of appropriate palliative care.

John Sellors and Guglielmo Ronco discuss HPV screening for precursors of cervical cancer.

Sally van der Meer discusses highlights from the September journal in this issue's podcast, including a new treatment option for preventing bone mineral loss among pre-menopausal women receiving hormone therapy for early breast cancer.

The Lancet Oncology podcast - a global health theme for the August issue. Editor David Collingridge discusses the highlights, including cancer survival from five continents, and a review of cancer issues in Africa.

TLO Editor David Collingridge discusses some highlights from the July issue: radiofrequency ablation showing promise for the treatment of lung cancer; how a rare form of obesity could negatively affect treatment outcomes; and a discussion of a recent meeting at IARC in Lyon, France, concerning the latest evidence on smoke-free policies and the effects on public health.

Emma Cannell and Sally van der Meer discuss highlights from the June issue: a prospective pilot study assessing the role of stellate-ganglion block to treat hot flushes in survivors of breast cancer; also discussed is a Personal View about cancer of unknown primary (CUP), and the Leading Edge on public confidence in Merck's HPV vaccine.

Editor David Collingridge discusses highlights from the May issue: the natural history of cervical intraepithelial neoplasia; the effect of screening on prostate-cancer mortality in the USA and UK; and the launch of a series of reviews about cancer in indigenous populations, starting this month with cancer among indigenous Polynesians.

Editor David Collingridge discusses highlights from the April issue including: encouraging results from the START trials suggest fewer fractions of radiotherapy could revolutionise treatment of early stage breast cancer; how a phase II study investigating yttrium-90 labelled ibritumomab could have an important future role in the treatment of follicular non-Hodgkin lymphoma, and finally the pressing need for increased recruitment of adolescents and young adults in to cancer trials.

Dr David Collingridge, Editor of the Lancet Oncology, discusses highlights of the March issue in the first Lancet Oncology podcast. Two main topics are discussed: a research article highlighting how individuals in the United States who are under-insured or who have no medical insurance are at an increased risk of presenting with late-stage cancers; non-whites are at a similarly increased cancer risk. Also featured is a Dutch study showing the potential benefits of a shared-care programme between family doctors and oncology clinics for the long-term follow-up of individuals diagnosed with cancer in childhood.

Harriet Rumgay (International Agency for Research on Cancer, France) discusses the recent global burden of cancer in 2020 attributable to alcohol consumption study

Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.

Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.

Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’